AAV-piggyBac Gene Composition for Durable Liver Enzyme Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for inherited metabolic disorders of the liver, such as urea cycle disorders and methylmalonic acidemia, face challenges in achieving long-term expression of delivered transgenes in target tissues, particularly in rapidly dividing cells like the juvenile liver, and lack effective gene therapy vectors that integrate into the host's genome for sustained therapeutic effects.
Innovation Solution
The use of adeno-associated virus (AAV) piggyBac transposon polynucleotides, comprising specific sequences of AAV ITR, piggyBac ITR, insulators, promoters, transgenes, and polyA sequences, to facilitate long-term expression of therapeutic genes in liver tissues, enhancing gene therapy efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of stationary object
If conventional gene therapy vectors are used, then initial gene delivery is achieved, but long-term expression of transgenes in rapidly dividing liver cells is lost
Solution Approach 1:
The patent combines two different gene delivery systems: AAV vectors (which provide stable nuclear localization) and piggyBac transposon systems (which provide stable genomic integration). By merging these systems into a hybrid AAV-piggyBac vector, the invention achieves both efficient delivery to liver cells and long-term stable expression even in rapidly dividing cells, resolving the contradiction between initial delivery and sustained expression.
Solution Approach 2:
The patent creates a composite gene therapy vector by integrating the piggyBac transposon system within the AAV capsid structure. This composite vector combines the advantages of AAV (stable nuclear entry, low immunogenicity) with the advantages of piggyBac (stable genomic integration, long-term expression), thereby achieving durable therapeutic effects in the liver despite cell division.
2Reliability
If frequent interventions are performed to maintain therapeutic enzyme levels, then therapeutic efficacy is maintained, but treatment complexity and patient burden increase
Solution Approach 1:
The patent employs a preliminary action by designing the AAV-piggyBac vector to autonomously integrate into the host genome upon delivery. This pre-programmed integration capability ensures that once the vector is delivered, it automatically establishes long-term expression without requiring subsequent interventions, thereby maintaining therapeutic efficacy while reducing treatment complexity.
Solution Approach 2:
The hybrid vector system is designed to be self-sustaining through autonomous genomic integration. After a single administration, the integrated transgene continues to express therapeutic enzymes independently without requiring repeated dosing or external maintenance, enabling the treatment system to serve itself long-term.
3Reliability
If liver transplantation is performed to treat metabolic disorders, then long-term survival is improved, but surgical risks and loss of native liver function occur
Solution Approach 1:
The patent introduces an intermediary solution—a gene therapy vector that delivers functional copies of defective metabolic enzymes directly to the patient's own liver cells. This intermediary approach corrects the underlying metabolic defect without requiring removal of the native liver, thereby achieving long-term survival improvement while avoiding surgical risks and preserving native liver function.
Solution Approach 2:
The gene therapy enables the patient's own liver to self-correct its metabolic dysfunction by producing the missing or defective enzymes. The therapeutic genes integrate into the liver genome and instruct liver cells to produce functional enzymes, allowing the native liver to continue performing its essential functions while corrected, eliminating the need for transplantation.
Data Source
AI summary
The present disclosure is directed to compositions and methods for the treatment of Metabolic Liver Disorders. The compositions and methods can comprise an adeno-associated virus (AAV) piggyBac polynucleotide comprising a transgene. The transgene may comprise ornithine transcarbamylase (OTC) or methylmalonyl-CoA mutase (MUT1).